


PHARMACEUTICAL 2021

ASAVARA

Savara Inc Rank 245 of 409





PHARMACEUTICAL 2021

A SAVARA

Savara Inc Rank 245 of 409

The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Savara Inc is the variable Net Income, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is -196%, being 158% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	85,121
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,174
Liabilities, Non-Current	84
Other Assets	12,468
Other Compr. Net Income	959
Other Expenses	255
Other Liabilities	25,104
Other Net Income	-315
Property and Equipment	156
Research and Development	35,038
Revenues	257
Selling, General and Administrative Expense	14,264

Output Variable	Value in 1000 USD
Assets	97,745
Liabilities	33,362
Expenses	49,557
Stockholders Equity	64,383
Net Income	-49,615
Comprehensive Net Income	-49,136
Economic Capital Ratio	-196%